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Abstract
Gain-of-function mutations in KIT receptor in humans are associated with gastrointestinal stromal 
tumors (GIST), systemic mastocytosis (SM), and acute myelogenous leukemia (AML). The 
intracellular signals that contribute to oncogenic KIT induced myeloproliferative disease (MPD) 
are poorly understood. Here, we show that oncogenic KITD814V induced MPD occurs in the 
absence of ligand stimulation. The intracellular tyrosine residues are important for KITD814V 
induced MPD, albeit to varying degrees. Among the seven intracellular tyrosines examined, 
tyrosine 719 alone plays a unique role in regulating KITD814V induced proliferation and survival 
in vitro, and MPD in vivo. Importantly, the extent to which AKT, ERK and Stat5 signaling 
pathways are activated via the seven intracellular tyrosines in KITD814V impacts the latency of 
MPD and severity of the disease. Our results identify critical signaling molecules involved in 
regulating KITD814V induced MPD, which might be useful for developing novel therapeutic 
targets for hematologic malignancies involving this mutation.
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Introduction
The proto-oncogene KIT belongs to the receptor tyrosine kinase class III family, which 
includes the macrophage colony stimulating factor receptor (M-CSFR), the platelet-derived 
growth factor receptor (PDGFR), as well as the F1 cytokine receptor (FLT3) (1). The KIT 
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receptor plays a crucial role in cell proliferation, differentiation, survival and migration 
through activation of diverse signaling pathways (2). Binding of its ligand, stem cell factor 
(SCF), induces KIT receptor dimerization and autophosphorylation on intracellular tyrosine 
residues leading to the recruitment and docking of src homology 2 (SH2) containing 
signaling molecules to the seven critical intracellular tyrosines (3). Although the individual 
and combined importance of these tyrosines in normal KIT receptor signaling is beginning 
to emerge; the role of these tyrosines in oncogenic KIT induced myeloproliferative disease 
(MPD) is poorly understood. Furthermore, it is unclear whether these tyrosines play a 
unique, redundant or overlapping function in inducing MPD.
Activating mutations in KIT receptor have been shown to be involved in various human 
diseases including gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM), and 
acute myelogenous leukemia (AML) (4–7). An activating KIT mutation within the tyrosine 
kinase domain, such as KITD814V in mice or KITD816V in humans, results in ligand 
independent tyrosine kinase activity leading to constitutive autophosphorylation and 
activation of downstream signaling pathways (8, 9). As a result, KITD814V bearing cells 
demonstrate ligand independent proliferation in vitro and MPD in vivo (8–12). However, the 
intracellular mechanisms that contribute to KITD814V induced MPD are not known. In 
addition, primary hematopoietic stem and progenitors (HSC/Ps) bearing KITD814V show a 
further increase in proliferation in the presence of KIT ligand, SCF, relative to cells grown 
in the absence of SCF (11), which suggests that endogenous ligand stimulation may 
contribute to oncogenic KIT induced transformation in vivo. Therefore, it is still unclear 
whether ligand independent growth observed in vitro via KITD814V is sufficient to induce 
MPD in vivo or whether presence of SCF is necessary to drive MPD.
Although KIT mutations within the juxtamembrane domain found in GIST are highly 
sensitive to inhibition by imatinib (i.e. Gleevec), KIT mutations within tyrosine kinase 
domain involved in SM and AML, including KITD816V, are resistant to imatinib treatment 
(13–15). Currently, there are no therapies available for human diseases involving 
KITD816V mutation. Thus, it is important to identify signaling pathways that are involved 
in KITD814V induced MPD to develop novel therapeutic targets for diseases involving this 
mutation. Utilizing biochemical and genetic approaches, we demonstrate that endogenous 
ligand (i.e. SCF) binding is dispensable for KITD814V induced MPD. Furthermore, the 
intracellular tyrosine residues are important for KITD814V induced MPD, albeit to varying 
degrees. Among the seven intracellular tyrosines examined, tyrosine 719 alone plays a 
unique role in regulating KITD814V induced proliferation in vitro, and MPD in vivo. 
Importantly, tyrosine 719 is vital for the activation of PI3Kinase and Stat5 downstream from 
KITD814V. Our results identify critical signaling molecules downstream from KITD814V, 
which might be useful for developing therapeutic targets for hematologic malignancies 
involving oncogenic forms of KIT.
Materials and Methods
Chemicals, Mice and Cells
Chemicals, mice and cells used were described in supplementary materials and methods.
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Wild-type (WT) and mutant KIT or CHR receptors
The construction and expression of WT and mutant KIT or CHR receptors was described in 
supplementary methods.
Proliferation
Proliferation was assessed by conducting a thymidine incorporation assay as previously 
described (16) and described in detail in supplementary methods.
Western bloting
Western blot analysis was performed as previously reported (16).
Murine bone marrow transplantation
A single intraperitoneal injection of 150 mg/kg of 5-fluorouracil (5-FU) was given to 
C57BL/6 mice. LDMNCs were collected 72 hours post 5-FU injection and transduced with 
retrovirus encoding the various KIT or CHR constructs as described previously (16). 1 × 106 
transduced cells and 1 × 105 supporting fresh splenocytes from C57BL/6 mice were 
intravenously injected through tail vein into lethally irradiated (1100 cGY-split dose) 
recipient mice. Transplanted mice were monitored for MPD development and survival. Mice 
were harvested at moribund and bone marrow, spleen, thymus and peripheral blood were 
harvested for flow cytometric analysis, and histology by hematoxylin and eosin staining.
Statistics
All graphical data was evaluated by paired Student t- test and results were considered 
significantly different with p-value <0.05. All data are represented as mean values ± 
standard deviations (SD). Survival probability of transplanted mice cohorts were compared 
using a Kaplan-Meier Survival Analysis in which statistical significance was determined as 
p-values <0.05 by log rank test.
Results
Construction of wild-type and mutant chimeric KIT receptors
We and others have previously shown that KITD814V is sufficient to induce ligand 
independent growth in vitro as well as myeloproliferative disease (MPD) in vivo (8–11, 17). 
It is however unclear whether KITD814V induced ligand independent growth observed in 
vitro is sufficient to cause MPD in vivo or whether presence of endogenous SCF induced 
signals are essential for the development of MPD. To determine the contribution of ligand 
independent growth in KITD814V induced MPD in vivo, we generated a chimeric KIT 
receptor (CHR) in which the extracellular domain of KIT was replaced with the extracellular 
domain of human macrophage colony stimulating factor receptor (h-MCSFR) to inhibit the 
endogenous binding of murine SCF, but to maintain the transmembrane and intracellular 
domains of the murine KIT receptor (18, 19) (Figure S1A). This receptor allows studying 
the ligand independent functions of KIT receptor in vivo as it maintains the intracellular 
functions of KIT receptor intact without endogenous binding of murine SCF or M-CSF, but 
is specifically activated by human M-CSF (18, 19). The wild-type chimeric receptor (WT 
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CHR) is functionally and biochemically similar to the wild-type endogenous KIT receptor as 
previously reported (18, 19). In addition, we constructed a mutant chimeric receptor 
(CHRD814V) that contains an oncogenic mutation of aspartic acid to valine at residue 814 
of the WT CHR (Figure S1A). Parental and chimeric KIT receptors with or without D814V 
mutation were cloned into a bicistronic retroviral vector, MIEG3, which expresses EGFP 
through an internal ribosome entry site as previously described (18, 19).
Ligand independent growth is sufficient to induce KITD814V induced MPD in vivo
We first verified whether our constructed chimeric KIT receptors function similar to their 
wild-type and KITD814V counterparts. We performed proliferation assay in 32D myeloid 
cells bearing parental or chimeric KIT receptors with or without D814V mutation by 
assessing thymidine incorporation. As expected, cells bearing KITD814V or CHRD814V 
showed similar levels of ligand independent growth (Figure S1B). In contrast, cells bearing 
WT KIT or WT CHR showed minimal thymidine incorporation in the absence of growth 
factors (Figure S1B). In addition, cells bearing WT CHR showed increased growth in the 
presence of human M-CSF, but not murine M-CSF (Figure S1C). These findings 
demonstrate that chimeric receptors (WT CHR and CHRD814V) function in a manner 
similar to their parental counterparts with respect to ligand independent growth and 
specifically respond to human M-CSF, but not murine M-CSF. Therefore, these chimeric 
receptors could be used to determine the impact of ligand independent growth in KITD814V 
induced MPD in vivo.
To determine the role of ligand independent growth in KITD814V induced MPD in vivo, we 
used a murine transplantation model that we have previously described (17). Low density 
mononuclear cells (LDMNC) from 5-FU-treated C57BL/6 mice were transduced with WT 
CHR, WT KIT, KITD814V or CHRD814V, and sorted cells were transplanted into lethally 
irradiated recipient mice. Transplanted mice were monitored for MPD development and 
survival. Consistent with our previous results, all mice transplanted with WT CHR or WT 
KIT bearing cells appeared normal and healthy past 180 days post transplantation (Data not 
shown). In contrast, all recipient mice transplanted with KITD814V or CHRD814V bearing 
cells died within 81 days of transplantation (Figure S2A). No significant difference in the 
survival of mice transplanted with cells bearing KITD814V or CHRD814V was observed 
suggesting that endogenous SCF mediated stimulation of KITD814V receptor is not 
necessary for KITD814V induced MPD in vivo. Mice transplanted with cells expressing 
CHRD814V developed a series of fatal diseases, including MPD, as seen by a significant 
increase in white blood cell counts compared to WT CHR controls (Figure S2B). In 
addition, mice transplanted with CHRD814V-bearing cells showed splenomegaly (Figure 
S2C). Figure S2D shows representative pictures of spleen and liver from mice transplanted 
with cells bearing either WT CHR or CHRD814V.
Histologic analysis of bone marrow (BM), spleen, liver and lungs from mice transplanted 
with CHRD814V bearing cells showed signs of MPD including infiltration of immature 
cells in BM and disruption of the normal architecture of red and white pulp in spleen (Figure 
S2E). Furthermore, flow cytometric analysis of peripheral blood, spleen and BM from mice 
transplanted with cells bearing CHRD814V showed increase in the presence of Gr-1 and 
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Mac-1-positive cells compared to mice transplanted with cells bearing WT CHR (Figure 
S2F). Some mice transplanted with cells bearing CHRD814V also demonstrated 
erythroleukemia, B-cell and T-cell lymphomas in addition to MPD, similar to other 
published models of oncogene-induced MPD (data not shown) (20). Taken together, these 
results indicate that KITD814V mutation does not require a direct engagement with its 
ligand SCF to induce MPD in vivo.
Intracellular tyrosine residues in KITD814V are essential for ligand independent growth in 
vitro
We next focused our studies to determine the importance of intracellular tyrosine residues in 
KITD814V induced ligand independent growth. To address this, we constructed a 
CHRD814V mutant receptor (CHRD814V-F7) in which all the intracellular tyrosine 
residues were converted to phenylalanine by site directed mutagenesis as shown in Figure 
1A. 32D cells were transduced with WT CHR, CHRD814V or CHRD814V-F7, sorted to 
homogeneity based on EGFP expression and used to perform proliferation assay. Consistent 
with our earlier result (Figure S1B), cells bearing CHRD814V, but not WT CHR, showed 
ligand independent growth (Figure 1B). However, conversion of all the seven intracellular 
tyrosine residues in CHRD814V to phenylalanine (CHRD814V-F7) resulted in loss of 
ligand independent growth (Figure 1B). These results suggest that intracellular tyrosine 
residues in KITD814V are essential for ligand independent growth.
To identify which of the tyrosine residue plays a critical role in KITD814V induced ligand 
independent growth in vitro and transformation in vivo, we generated 7 different single 
tyrosine add-back mutants at residues 567, 569, 702, 719, 728, 745 and 934 in the KIT 
intracellular domain using CHRD814V-F7 as the template (Figure 2A). These CHRD814V 
mutant receptors were designated CHRD814V-Y567, CHRD814V-Y569, CHRD814V-
Y702, CHRD814V-Y719, CHRD814V-Y728, CHRD814V-Y745 and CHRD814V-Y934. 
32D cells, which lack endogenous KIT receptor, were infected with these mutant 
CHRD814V receptors and sorted to homogeneity. A similar level of expression of these 
receptors was observed by western blot analysis (Figure 2B). As seen in Figure 2C, 32D 
cells bearing only the chimeric receptor harboring tyrosine residue at position 719 
(CHRD814V-Y719) was sufficient to induce ligand independent growth to a level similar to 
cells bearing the CHRD814V receptor. The other tyrosine add-back CHRD814V receptors 
induced modest to no ligand independent proliferation (Figure 2C). Similar results were 
observed in transduced primary HSC/Ps from KitW-sh/W-sh mice lacking endogenous KIT 
(Data not shown). In addition, cells bearing CHRD814V showed significantly increased 
survival compared to WT CHR bearing cells in the absence of growth factors and loss of 
intracellular tyrosine residues in CHRD814V (CHRD814V-F7) abrogated ligand 
independent survival (Figure S3A). Among all the single tyrosine add-back CHRD814V 
receptors, CHRD814V-Y719 was the only receptor whose expression maintained survival at 
a level similar to that of CHRD814V receptor (Figure S3A). There was no significant 
difference in the cycling status of cells bearing various mutant CHRD814V receptors, 
including CHRD814V and CHRD814V-Y719, when grown in the absence of growth factors 
(Figure S3B). These results demonstrate that intracellular tyrosine residues in KITD814V 
receptor are essential for ligand independent growth. Among these tyrosine residues, 
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tyrosine at residue 719, which is the binding site for class IA PI3Kinase regulatory subunit 
p85α, is sufficient to rescue ligand independent proliferation in vitro to CHRD814V levels.
Intracellular tyrosine residues in KITD814V contribute to MPD in vivo, albeit to varying 
extent
To determine the physiologic role of the intracellular tyrosine residues in KITD814V 
induced MPD in vivo, we transduced primary HSC/Ps from 5-FU-treated C57BL/6 mice 
with WT CHR, CHRD814V or CHRD814V with none or single tyrosine add-back mutants. 
Transduced cells showing similar transduction efficiencies were sorted to homogeneity and 
transplanted into lethally irradiated recipient mice. Mice were monitored for MPD 
development and survival. While mice transplanted with cells bearing WT CHR showed no 
signs of disease and survived throughout the study, mice transplanted with cells bearing 
CHRD814V (red line) succumbed to death within 80 days of transplantation and developed 
a fatal MPD (Figure S2A and Figure 3A). In addition, mice transplanted with cells bearing 
CHRD814V-F7 (black line), which lack all the seven intracellular tyrosine residues, 
significantly delayed MPD development and prolonged overall survival (Figure 3A-1). In 
the CHRD814V-F7 group, only 70% of the mice died within 180 days of transplantation and 
remaining 30% showed no signs of disease and appeared normal. These data suggest that the 
intracellular tyrosine residues in KITD814V are critical for efficient transformation in vivo.
Consistent with in vitro proliferation, among all the mice transplanted with cells bearing 
various CHRD814V mutant receptors, only recipient mice expressing CHRD814V-Y719 
(blue line) showed similar MPD progression and survival as the CHRD814V bearing mice 
(Figure 3A-5). The median time of survival in these two groups was 60 days for 
CHRD814V vs 55 days for CHRD814V-Y719. In addition, recipient mice with cells bearing 
CHRD814V-Y567, CHRD814VY569, CHRD814V-Y728CHRD814V-Y745 and 
CHRD814V-Y934 showed a significant delay in MPD development and survival compared 
to CHRD814V bearing mice (Median time of survival 105, 128,95,104 and 68 days, 
respectively, *p<0.05). Restoration of Y702 demonstrated a modest but non-significant 
delay in the disease onset compared to KITD814V bearing mice (Median time of survival 76 
days, p=0.077). Consistent with the survival data, histological analysis of bone marrow, 
spleen, liver and lungs from the recipient mice transplanted with cells bearing various single 
tyrosine add-back CHRD814V mutants showed variable degree of infiltration of immature 
cells relative to CHRD814V bearing mice or CHRD814V-Y719 bearing mice (Figure S2E 
and Figure 3B). These results suggest that among the seven intracellular tyrosine residues in 
KITD814V, tyrosine residue at 719 is sufficient to induce fully penetrant MPD in vivo. 
Other tyrosine residues at 567, 569, 702, 719, 728, 745 and 934 do contribute to KITD814V 
induced MPD, however to a lesser extent, resulting in delayed disease onset and reduced 
severity.
Differential activation of PI3Kinase, Stat5, and ERK MAP kinase in cells bearing various 
single tyrosine add-back CHRD814V mutant receptors
To assess the biochemical basis for the differential role of single tyrosine add-back 
CHRD814V mutants in ligand independent growth and MPD, activation of AKT, Stat5 and 
ERK, which are known to be critical for KITD814V induced MPD, was analyzed (11, 17, 
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21, 22). As seen in Figure 4A, constitutive phosphorylation of AKT, Stat5, and ERK was 
observed in cells bearing CHRD814V, but not in WT CHR bearing cells. Interestingly, loss 
of seven intracellular tyrosine residues in CHRD814V resulted in complete abrogation of the 
constitutive activation of AKT, Stat5 and ERK (Figure 4A, lane 11). Importantly, among the 
single tyrosine add-back CHRD814V mutants, only restoring tyrosine 719 completely 
rescued the robust constitutive phosphorylation of AKT, Stat5, and ERK observed in 
CHRD814V expressing cells (Figure 4A, lane 7). Cells bearing CHRD814V-Y702 and 
CHRD814V-Y728 showed robust activation of AKT and ERK, but not Stat5 (Figure 4A, 
lanes 6 and 8, respectively). Furthermore, a modest constitutive activation of AKT and ERK 
was observed in cells bearing CHRD814V-Y569 (Figure 4A, lane 5). In contrast, no 
activation of AKT, Stat5 and ERK was observed in cells bearing CHRD814V-Y567, 
CHRD814V-Y745 or CHRD814V-Y934 (Figure 4A, lanes 4, 9 and 10, respectively). These 
results suggest that differential activation of AKT, Stat5 and ERK in cells bearing various 
single tyrosine add-back CHRD814V mutants likely contributes to variable level of disease 
progression and survival of transplanted mice.
Class IA PI3Kinase regulatory subunit p85α is essential for constitutive activation of Stat5 
in KITD814V bearing cells
The above results showed constitutive activation of both AKT and Stat5 in cells bearing 
CHRD814V and CHRD814V-Y719, but not other CHRD814V mutant receptors. These 
results suggest that tyrosine 719 (binding site for p85α subunit) mediated signaling events 
might be required for constitutive activation of Stat5 in KITD814V bearing cells. To test 
this, we infected primary HSC/Ps from WT and p85α−/− mice with WT KIT or KITD814V, 
sorted the cells and determined constitutive phosphorylation of Stat5 by western blotting. 
Constitutive phosphorylation of Stat5 was observed in WT cells bearing KITD814V, but not 
WT KIT bearing cells (Figure 4B). Deficiency of p85α resulted in significantly reduced 
KITD814V induced activation of Stat5 (Figure 4B). These results demonstrate that p85α is 
essential for constitutive activation of Stat5 in KITD814V bearing cells.
PI3Kinase and Stat5 inhibitors suppress KITD814V induced ligand independent growth
Since cells bearing KITD814V show constitutive activation of AKT, Stat5 and ERK, we 
examined whether inhibition of PI3Kinase, Stat5 or ERK activation would suppress 
KITD814V induced ligand independent proliferation. We treated cells bearing WT CHR or 
CHRD814V with the PI3Kinase inhibitor LY294002, Stat5 inhibitor, or MEK inhibitor 
PD0325901, and assayed proliferation by thymidine incorporation. As seen in Figure 4C, 
LY294002 treatment completely suppressed the constitutive growth of cells bearing 
CHRD814V. In contrast, Stat5 inhibitor treatment showed only a partial but significant 
repression in the constitutive growth of cells bearing CHRD814V. In addition, MEK 
inhibitor treatment showed no significant effect on the constitutive growth of cells bearing 
CHRD814V. These results suggest that activation of PI3Kinase and Stat5 plays an essential 
role in KITD814V induced ligand independent growth. Since Stat5 inhibitor only partially 
suppressed the constitutive growth of cells bearing CHRD814V, PI3Kinase may also 
regulate the activation of other signaling molecules in addition to Stat5 in cells bearing 
KITD814V.
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PI3Kinase pathway is essential for KITD814V induced ligand independent proliferation via 
AKT and mTOR signaling
To further determine the signaling molecules downstream of PI3Kinase that might 
contribute to the growth of KITD814V bearing cells, we analyzed the involvement of AKT 
and mTOR. For this, we starved the cells bearing KITD814V in serum- and cytokine-free 
medium for 6 hours and performed proliferation assays in the presence of indicated amounts 
of specific PI3Kinase inhibitor (GDC-0941), AKT inhibitor (AKT inhibitor VIII), or mTOR 
inhibitor (AZD8055) by thymidine incorporation. As seen in Figure 5A, KITD814V induced 
ligand independent proliferation is significantly suppressed in the presence of the specific 
inhibitors of PI3Kinase, mTOR and AKT, which suggests that PI3Kinase pathway is 
essential to KITD814V induced ligand independent proliferation via AKT and mTOR 
signaling. In contrast, although the MEK inhibitor (PD0325901) did not significantly repress 
KITD814V induced proliferation even at high doses (Figure 4C), a significant further 
suppression in ligand independent proliferation in KITD814V bearing cells in the presence 
of PI3Kinase inhibitor (GDC-0941) and MEK inhibitor (PD0325901) was observed (Figure 
5B). These results suggest that while MEK/ERK pathway alone is not critical; it can 
cooperate with the PI3Kinase pathway to regulate KITD814V induced ligand independent 
proliferation.
Discussion
Our studies demonstrate that the direct binding of the ligand SCF to KITD814V receptor is 
not necessary to induce MPD and intracellular tyrosines are critical to this process. Mice 
bearing either the parental KITD814V receptor or the chimeric CHRD814V receptor 
(lacking the ability to be activated via its ligand SCF) show similar potency at inducing 
MPD with similar median survival. Furthermore, no significant difference in disease 
manifestation was observed between the two transplanted groups. Importantly, intracellular 
tyrosines show a critical role in CHRD814V induced MPD and survival. Loss of seven 
critical tyrosine residues in CHRD814V, which are known to activate PLC-γ (728) (23, 24), 
PI3Kinase [p85α; 719] (25), Src family kinases (567 & 569) (26–28), Grb2 (702) (29), Grb7 
(934) (29) and Ras-GAP (745) profoundly impaired disease onset and prolonged the 
survival of transplanted mice. Only 70% mice that were transplanted with cells bearing 
CHRD814V-F7 succumb to death with very long latency, while 30% mice were free of 
disease and survived for the remaining duration of the study. Using transduced primary 
HSC/Ps, we have previously demonstrated that KITD814V not only induces ligand 
independent growth or responds to SCF, but also synergizes with IL-3 and macrophage 
colony-stimulating factor (M-CSF) receptors to further enhance the growth of these cells in 
vitro. This suggests that KITD814V induced ligand-independent growth and its ability to 
cooperate with other cytokines might also contribute to activating KIT induced MPD (11). 
Furthermore, KIT has also been shown to cooperate with granulocyte macrophage colony-
stimulating factor (GMCSF) in a kinase independent manner (30) and to synergize with 
granulocyte colony-stimulating factor (G-CSF) to induce proliferation (31). Therefore, it is 
conceivable that CHRD814V-F7 is not sufficient to induce robust proliferation without 
growth factor in vitro, but may cooperate with additional cytokine receptors, such as IL-3, 
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M-CSF and /or G-CSF receptors to induce MPD in the 70% transplanted animals in a 
significantly delayed and milder manner.
In an effort to assess the role of individual tyrosine mediated signals in KITD814V induced 
MPD, we employed a unique approach. While single point mutations in important tyrosine 
residues have been shown to affect KIT function (32, 33), we felt that the approach of 
interfering with the binding of one or two SH2 binding proteins to CHRD814V, when all 
other SH2 proteins still retain the ability to bind may not allow for complete assessment of 
the importance of signals emanating from a single pathway, since it is possible that the 
remaining SH2 consisting proteins may compensate for the loss of a single binding site. We 
therefore employed a strategy where we could assess the role of an individual tyrosine 
induced pathway in KITD814V induced MPD. Using a version of the receptor that lacked 
all 7 tyrosines (i.e. CHRD814V-F7) as the template, we restored each of the SH2 binding 
sites from phenylalanine to tyrosine and tested their ability to induce growth in vitro and 
MPD in vivo, along with their potential to activate downstream signaling molecules known 
to be involved in KITD814V induced MPD, including AKT, ERK and Stat5. We show a 
unique role for tyrosine 719 in regulating KITD814V induced MPD. We show that restoring 
this site alone in the CHRD814V-F7 receptor is sufficient to completely rescue ligand 
independent growth in vitro, MPD in vivo and activation of AKT, ERK and STAT5, similar 
to the CHRD814V receptor. Importantly, while the remaining add-back mutant receptors 
showed minimal rescue in ligand independent growth in vitro; in vivo mice bearing these 
receptors demonstrated delayed MPD onset and prolonged latency compared to CHRD814V 
or CHRD814V-Y719 receptor bearing mice. These results suggest that although ligand 
independent growth is sufficient for KITD814V induced MPD in vivo, presence of SCF and 
other cytokines might further regulate the MPD phenotype.
The variable onset of MPD and latency in mice transplanted with cells bearing various add-
back mutant receptors was associated with differential rescue in the activation of AKT, ERK 
and STAT5. In general, add-back CHRD814V mutants that lacked the ability to rescue the 
activation of AKT, ERK and STAT5, such as CHRD814V-F7 receptor bearing mice, 
demonstrated prolonged latency, while receptors demonstrating rescue in the activation of 
AKT and ERK, such as the CHRD814V-Y702 receptor bearing mice, resulted in MPD, 
albeit at a slower rate. In contrast, receptors that robustly activated all three signaling 
molecules (ERK, AKT and Stat5) such as the CHRD814V-Y719 and the CHRD814V 
receptor, showed the shortest disease latency. Thus, KITD814V induced MPD in vivo is 
largely dependent on the level of activation of AKT, ERK and STAT5, which to a large 
extent is regulated by signals emanating from tyrosine 719, suggesting that signals 
emanating from tyrosine 719 play a dominant role in regulating MPD, while the remaining 
tyrosine initiated signals contribute to MPD, albeit to a lesser extent. Thus, the impairment 
in the activation of essential signaling pathways is likely to contribute to a significant delay 
in the onset of MPD in mice bearing remaining add-back mutants of KITD814V.
While recent studies have suggested that persistent activation of PI3Kinase and Stat5 is 
frequently observed in hematologic malignancies as well as in solid tumors (34, 35), how 
exactly PI3Kinase contributes to KITD814V induced MPD and/or Stat5 activation is 
unclear. We show that tyrosine 719 in KITD814V (binding site for p85α) contributes to the 
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activation Stat5. In cells expressing CHRD814V-F7, no binding of p85α is observed and 
consistently no constitutive activation of Stat5 is observed (data not shown). Furthermore, 
deficiency of p85α in HSC/Ps expressing KITD814V results in complete inhibition of Stat5 
activation. Importantly, restoring 719 from phenylalanine to tyrosine in CHRD814V-F7 
completely rescues Stat5 activation. Thus, binding of p85α to tyrosine 719 in KITD814V is 
critical for Stat5 activation. These results suggest that PI3Kinase mediated signaling is 
essential for constitutive activation of Stat5 in KITD814V bearing cells. While treatment of 
cells bearing KITD814V with the PI3Kinase, AKT and mTOR inhibitors profoundly 
suppressed the ligand independent growth in vitro, treatment with Stat5 inhibitor only 
partially repressed the constitutive growth. These results, while consistent with our 
biochemical findings, suggest that in addition to Stat5, PI3Kinase might cooperate with 
other signaling molecules including the ERK pathway downstream from KITD814V to 
induce MPD. Taken together, our studies determine the contribution of SCF to KITD814V 
induced MPD in vivo, and also identify critical tyrosine residues and signaling pathways 
involved in KITD814V induced MPD.
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Figure1. Intracellular tyrosine residues in KIT receptor are essential for KITD814V induced 
ligand independent growth in vitro
(A) Schematic of WT CHR, CHRD814V and CHRD814V-F7. The D814V mutation in the 
kinase domain of KIT is indicated in the mutant chimeric receptors. A chimeric receptor 
(CHRD814V-F7) was constructed in which seven critical tyrosine residues (Y) at indicated 
positions were changed to phenylalanine (F) by site-directed mutagenesis using CHRD814V 
as a template. (B) Cells bearing WT CHR, CHRD814V or CHRD814V-F7 receptors were 
subjected to proliferation assay in the presence or absence of IL-3 by thymidine 
incorporation. Bars denote the mean thymidine incorporation (CPM ± SD) from one of three 
independent experiments performed in quadruplicate. *p<0.05, CHRD814V vs. 
CHRD814V-F7.
Ma et al. Page 13
Leukemia. Author manuscript; available in PMC 2015 March 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Differential contribution of intracellular tyrosine residues in KIT receptor to 
KITD814V induced ligand independent growth in vitro
(A) Schematic of mutant CHRD814V receptors. In the single tyrosine add-back mutant 
CHRD814V receptors, phenylalanine at indicated positions in the CHRD814V-F7 receptor 
were restored to tyrosines on an individual basis. (B) Equal amounts of protein lysates from 
cells bearing MIEG3 vector or indicated chimeric receptors was subjected to western blot 
analysis using an anti-KIT antibody. Similar results were observed in two additional 
experiments. (C) 32D cells bearing the indicated chimeric receptors were starved of serum 
and growth factors for 6 hours and subjected to thymidine incorporation assay in the absence 
of growth factors. Bars denote the mean thymidine incorporation (CPM± SD) from one of 
the three experiments performed in replicates of four. *p<0.05.
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Figure 3. Intracellular tyrosine residues in KIT receptor are essential for KITD814V induced 
MPD in vivo
(A) Kaplan-Meier survival analysis of mice transplanted with cells bearing indicated single 
tyrosine add-back mutant CHRD814V receptors (n=4 to 13 per group). Results show that 
loss of seven tyrosine residues in CHRD814V significantly delayed MPD development and 
prolonged overall survival (median survival= 140 days, n=13, *p<0.05). Restoration of 
Y719 alone is sufficient to induce MPD in vivo (median survival= 55 days, n=7, *p<0.05). 
Compared to CHRD814V, restoration of Y567, Y569, Y728, Y745 and Y934 demonstrated 
a significant delay in disease onset in transplanted mice (median survival= 95–128 days, n=4 
to 13, *p<0.05). There is a modest but non-significant delay in the survival of the recipient 
mice bearing CHRD814V-Y702 compared to CHRD814V bearing mice (median 
survival=76 days, n=4, *p=0.077). (B) Histopathologic analysis of bone marrow, spleen, 
liver and lung from mice transplanted with cells bearing various single tyrosine add-back 
mutant CHRD814V receptors. Bone marrow, spleen, liver and lung from mice transplanted 
with cells bearing various single tyrosine add-back mutant CHRD814V receptors were 
harvested, fixed in 10% buffered formalin, sectioned, and stained with hematoxylin and 
eosin. Shown are representative tissue sections from mice transplanted with cells bearing 
various single tyrosine add-back mutant CHRD814V. Normal erythroid and myeloid 
components in bone marrow, spleen, liver and lungs were replaced by sheets of immature 
tumor cells to various degrees in all the representative animals, but predominately in 
CHRD814V-Y719 (panel 4) followed by CHRD814V-Y745 (panel 6) and CHRD814V-
Y728 (panel 5), respectively (first row).
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Figure 4. Involvement of AKT, ERK and Stat5 signaling in KITD814V induced ligand 
independent growth
(A) Cells bearing the indicated chimeric receptors were starved in serum- and growth factor-
free medium for 8 hours. Starved cells were lysed and equal amount of protein lysates were 
subjected to western blot analysis using an anti-phospho-Stat5, phospho-AKT, phospho-
ERK, and total Stat3 antibodies as indicated. Similar results were observed in two to three 
independent experiments. (B) Primary BM derived progenitors expressing WT KIT or 
KITD814V receptors from WT or p85α −/− mice were starved for 8 hours from serum and 
cytokines. Equal amount of protein was subjected to western blot analysis using an anti-
phospho-Stat5 and an anti total-Stat5 antibody. Similar results were observed in two 
independent experiments. (C) Cells bearing WT CHR or CHRD814V were starved of serum 
and growth factors for 6 hours and subjected to proliferation assay in the presence or 
absence of indicated amounts of PI3Kinase inhibitor (LY294002), Stat5 inhibitor or MEK 
inhibitor (PD0325901). Assays were performed in the presence of IL-3 (10 ng/mL) for cells 
expressing WT CHR, whereas for CHRD814V bearing cells in the absence of growth 
factors. Bars denote the mean thymidine incorporation (CPM ± SD) from one of two-three 
independent experiments performed in quadruplicate. *p <0.05.
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Figure 5. PI3Kinase pathway is essential for KITD814V induced ligand independent 
proliferation via AKT and mTOR signaling
(A) 32D cells bearing KITD814V receptor were starved in serum- and growth factor-free 
media for 6 hours and subjected to proliferation assay in the absence of growth factors by 
thymidine incorporation. The proliferation assay was performed in the presence of 
individual inhibitors including PI3K inhibitor (GDC-0941), AKT inhibitor (AKT inhibitor 
VIII), or mTOR inhibitor (AZD8055) at indicated concentrations. Bars denote the mean 
thymidine incorporation (CPM ± SD) from one of two independent experiments performed 
in quadruplicate. *p <0.05. (B) 32D cells bearing KITD814V receptor were starved in 
serum- and growth factor-free media for 6 hours and subjected to proliferation assay in the 
absence of growth factors by thymidine incorporation. The proliferation assay was 
performed in the presence of PI3Kinase inhibitor (GDC-0941) and MEK inhibitor 
(PD0325901) individually or in a combination at indicated concentration. Bars denote the 
mean thymidine incorporation (CPM ± SD) from one of two independent experiments 
performed in quadruplicate. *p <0.05.
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